Sodium nitrite oral - Theravasc

Drug Profile

Sodium nitrite oral - Theravasc

Alternative Names: TV-1001; TV1001SR

Latest Information Update: 04 Aug 2016

Price : $50

At a glance

  • Originator TheraVasc
  • Developer TheraVasc; University of Colorado at Boulder
  • Class Antidotes; Antihypertensives; Nitrites; Small molecules; Sodium compounds; Vasodilators
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Diabetic angiopathies; Diabetic neuropathies
  • Phase I/II Vascular disorders

Most Recent Events

  • 02 Aug 2016 Efficacy and adverse events data from a phase II trial in Diabetic angiopathies released by TheraVasc
  • 02 Aug 2016 Efficacy and adverse events data from a phase II trial in Diabetic neuropathies released by TheraVasc
  • 02 Aug 2016 TheraVasc completes a phase II trial in Diabetic neuropathies (Neuropathic pain) in USA prior to August 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top